CureDuchenne Ventures Invests in hC Bioscience and its Novel tRNA-Based Therapeutic Approach for Duchenne Muscular Dystrophy
Hawken Miller is a journalist, bringing his experience writing for outlets like The Washington Post and BioNews, along with his personal experience living with Duchenne muscular dystrophy, to CureDuchenne. Learn more about Hawken here.
Find a clinical trial that works for you! Clinicaltrials.gov, managed by the U.S. National Library of Medicine, includes 439,599 research studies in 50 states and 221 countries. Many of those […]
CureDuchenne was the original funder of cTAP. We congratulate the consortium and other authors on their recent publication looking at large data sources and investigating effects of different genotypes on […]
REGENXBIO’s Senior Director and Clinical Development Lead, Dr. Jahannaz Dastgir and Dr. Veerapandiyan from Arkansas Children’s Hospital share updates about RGX-202, an investigational gene therapy for the treatment of Duchenne […]
Attending a concert or sporting event is a fun activity for everyone. With proper planning and research, people with Duchenne can also participate and enjoy their favorite band or sports team with their friends.
Savvy Business Veteran Ryan T. Meardon Bolsters Executive Team, Bringing High-Level Strategic Planning and Leadership to Global Rare Disease Nonprofit Newport Beach, Calif. – February 1, 2023 – CureDuchenne, a global […]
CureDuchenne is made up of people from all walks of life who share a common purpose — to find a cure for Duchenne and support all the families and patients […]
